Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
6
4
4
5
5
3
Research & Development
5
3
3
4
7
2
Operating Expenses
12
8
7
11
14
7
Other Non Operating Income (Expenses)
--
--
0
0
0
0
Pretax Income
-12
-8
-7
-11
-14
-7
Income Tax Expense
--
--
--
--
--
--
Net Income
-12
-8
-7
-11
-14
-7
Net Income Growth
71%
14%
-36%
-21%
100%
0%
Shares Outstanding (Diluted)
13.78
6.37
3.4
1.2
0.89
0.49
Shares Change (YoY)
100%
87%
184%
35%
82%
32%
EPS (Diluted)
-0.88
-1.28
-2.3
-9.47
-16.07
-14.69
EPS Growth
-19%
-44%
-76%
-41%
9%
-28.99%
Free Cash Flow
-9
-6
-8
-9
-12
-6
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
--
--
--
--
-14
-7
EBITDA Margin
--
--
--
--
0%
0%
D&A For EBITDA
--
--
--
--
0
0
EBIT
-12
-8
-7
-11
-14
-7
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are Hoth Therapeutics Inc's key financial statements?
According to the latest financial statement (Form-10K), Hoth Therapeutics Inc has a total asset of $7, Net loss of $-8
What are the key financial ratios for HOTH?
Hoth Therapeutics Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Hoth Therapeutics Inc's revenue broken down by segment or geography?
Hoth Therapeutics Inc largest revenue segment is Transport, at a revenue of 5,380,500,000 in the most earnings release.For geography, Australia is the primary market for Hoth Therapeutics Inc, at a revenue of 7,586,800,000.
Is Hoth Therapeutics Inc profitable?
no, according to the latest financial statements, Hoth Therapeutics Inc has a net loss of $-8
Does Hoth Therapeutics Inc have any liabilities?
no, Hoth Therapeutics Inc has liability of 0
How many outstanding shares for Hoth Therapeutics Inc?
Hoth Therapeutics Inc has a total outstanding shares of 8.04